KNSA News and Press, Kiniksa Pharmaceuticals Ltd. From 07/25/23

2023-07-25 07:36:11 ET Kiniksa Pharmaceuticals press release ( NASDAQ: KNSA ): Q2 GAAP EPS of $0.21 beats by $0.38 . Revenue of $71.47M (+165.0% Y/Y) beats by $19.27M . Total revenue for the second quarter of 2023 included $54.5 million in ARCALYST net product ...

– ARCALYST ® (rilonacept) Q2 2023 net product revenue of $54.5 million – – ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint – – KPL-404 Phase 2 rheum...

2023-07-24 12:55:41 ET Kiniksa Pharmaceuticals ( NASDAQ: KNSA ) is scheduled to announce Q2 earnings results on Tuesday, July 25th, before market open. The consensus EPS Estimate is -$0.13 (+55.2% Y/Y) and the consensus Revenue Estimate is $52.2M (+93.5% Y/Y). Over the...

2023-07-24 11:02:24 ET Major earnings expected before the bell on Tuesday include: General Electric ( GE ) General Motors ( GM ) 3M ( MMM ) RTX ( RTX ) Verizon Communications ( VZ ) For further details see: Notable earnings before Tuesday'...

2023-07-19 15:25:11 ET Summary Innovations in the drug lineup, including ARCALYST, KPL-404, and Mavrilimumab, showcase Kiniksa's dedication to targeting challenging autoimmune and inflammatory conditions. ARCALYST's net product revenue in Q1 2023 summed to $42.7 million, with a fu...

HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio e...

2023-06-09 12:32:12 ET Summary Today, we take our first look at a commercial stage biopharma concern called Kiniksa Pharmaceuticals, Ltd. The company is seeing impressive growth from its primary drug asset and has an intriguing pipeline. An investment analysis follows in the p...

HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. Pacific Time (11:40 a...

2023-05-06 12:32:10 ET Kiniksa Pharmaceuticals, Ltd. (KNSA) Q1 2023 Earnings Conference Call May 2, 2023 08:30 ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Rag...

2023-05-02 12:40:33 ET Kiniksa Pharmaceuticals ( NASDAQ: KNSA ) rose ~14% on Tuesday after the Bermuda-headquartered biotech reported better-than-expected Q1 2023 financials and increased its full-year guidance for its main revenue generator Arcalyst pericarditis therapy. Ki...